]>
IRCT2015010112823N2 IRCT 2015-01-19 Vice Chancellor for Research and Technology, Semnan University of Medical Sciences Effect of the Platelet-Rich Plasma(PRP) injection in primary manifestations of knee osteoarthritis Effect of the Platelet-Rich Plasma (PRP) injection in primary manifestations of knee osteoarthritis in patients who refer to rheumatology clinic of Kowsar hospital, Semnan 2014-12-22 anticipated 60 Complete https://irct.ir/trial/12827 interventional Randomization: Not randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment. 2-3 primary manifestations of osteoarthritis. Intervention 1: In the first group (N=30) 3 CC autologous PRP by a syringe which covered in aluminum foil will be intraarticularly injected. The patient is not aware of the contents of the syringe (real injections). Intervention 2: For patients in the control group (n=30) an empty syringe which covered by aluminum foil prepared and its needle enter up to 5 mm into skin and fat tissue without entering into the joint space (Pseudo injection). Introduction:<br /> Osteoarthritis (OA) has high prevalence due to various reasons such as occupational and environmental conditions. Pain and discomfort decreased quality of life in patients with osteoarthritis. There is known treatment for the disease. According to the effect of PRP single injection in some reports, in this study we aimed to assess the effect of single injection of platelet-rich plasma(prp) on the symptoms in early stages of knee OA.<br /> Patient and methods:<br /> In randomized, double-blind, clinical trial 34 patients with early symptoms of knee osteoarthritis in the age range 40-65 years, with a history of chronic knee pain for at least 12 months and kellgren –lawrence radiological criteria were enrolled. Three ml of autologous prp injected in both knees for patients in case group patients and patients in the control group received placebo injected into the another joint. Patients were assessed at baseline and 3 and 6 months after the intervention by IKDC,EQ-VAS,WOMAK and tegner criteria.<br /> Result:<br /> The difference of the mean IKDC score before and three months after injection as well as three and six months after the injection was statistically significant in the two groups(p=0.040), but was not significant before and six months after injection.<br /> Difference of the WOMAC,EQ-VAS and tegner scores were not significant in the two groups.<br /> Conclusion:<br /> The results showed that based on the IKDC criteria, single platelet-rich plasma injection can be effective in pain relieving and improve the patients’ performance.<br />
public Dr. Jamileh Moghimi
Basidj Boulevard
Semnan Iran (Islamic Republic of) +98 23 3345 1336 moghimi_jam@yahoo.com Semnan University of Medical Sciences scientific Dr. Jamileh Moghimi
Basidj Boulevard
Semnan Iran (Islamic Republic of) +98 23 3345 1336 moghimi_jam@yahoo.com Semnan University of Medical Sciences Iran (Islamic Republic of) Inclusion criteria: 1- age 40-60 years, 2- a history of chronic knee pain for at least 12 months, 3-Kellgren-Lawrence radiological criteria for having developing osteoarthritis of the knee (grade 1 and 2). Exclusion criteria: 1. Thrombocytopenia, 2- taking anticoagulant agents during the past 2 weeks 3- taking immunosuppressive drugs, NSAIDs and corticosteroids, 4- liver or renal disease, 5- leukemia and lymphoma, 6- a history of malignancy, active malignant disease, 7- severe cardiovascular disease including congestive heart failure, myocardial infarction and cardiac arrhythmia, 8- bacterial arthritis at least during last 6 months, 9- intra-articular injection of steroid or hyaluronic acid during the last 6 months, 10- use of cigarettes and tobacco 11- fever and systemic infections and local infection in injection site. 40 years 60 years Both Gonarthros M17 Treatment - Drugs Treatment - Drugs In the first group (N=30) 3 CC autologous PRP by a syringe which covered in aluminum foil will be intraarticularly injected. The patient is not aware of the contents of the syringe (real injections). For patients in the control group (n=30) an empty syringe which covered by aluminum foil prepared and its needle enter up to 5 mm into skin and fat tissue without entering into the joint space (Pseudo injection). Pain. Timepoint: Befor and 3 and 6 months after intervention. Method of measurement: IKDC, EQ-VAS and Tegner criteria. Physical Activities. Timepoint: 6 months after intervantion. Method of measurement: IKDC، EQ-VAS and Tegner criteria. Vice Chancellor for Research and Technology, Semnan University of Medical Sciences Approved 2015-01-13 Ethical committee, Semnan university of Medical Sciences Basidj Boulevard Semnan Iran (Islamic Republic of)